St 920 Emerging Drug Insight And Market Forecast

“ST-920 - Emerging Drug Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Fabry Disease in 7 Major Markets. A detailed picture of the ST-920 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020–2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary

ST-920 comprises an AAV vector carrying a GLA gene construct driven by a proprietary liver-specific promoter. ST-920 gene therapy is designed to enable a patient's liver to produce a long-lasting and continuous supply of the α-Gal A enzyme. The drug is currently in phase I/2 stage of development.

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around ST-920.
  • The report contains forecasted sales for ST-920 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Fabry Disease.
  • The report also features the SWOT analysis with analyst insights and key findings of ST-920.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ST-920 Analytical Perspective by DelveInsight

  • In-depth ST-920 Market Assessment

This report provides a detailed market assessment of ST-920 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.


  • ST-920 Clinical Assessment

The report provides the clinical trials information of ST-920 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights  

  • In the coming years, the market scenario for Fabry Disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.   
  • The companies and academics are working to assess challenges and seek opportunities that could influence ST-920 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Fabry Disease are giving market competition to ST-920 and launch of late-stage emerging therapies in the near future will significantly impact the market.  
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of ST-920.
  • Our in-depth analysis of the forecasted sales data of ST-920 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ST-920. 

Key Questions

  • Which company is developing ST-920 along with the phase of the clinical study?
  • What is the technology utilized in the development of ST-920?
  • What is the product type, route of administration and mechanism of action of ST-920?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ST-920 development?
  • What are the key designations that have been granted to ST-920?
  • What is the forecasted market scenario of ST-920?
  • What is the history of ST-920 and what is its future?
  • What is the forecasted sales of ST-920 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?  
  • What are the other emerging products available and how these are giving competition to ST-920?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

 

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assesment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

 Table 1 ST-920, Description

Table 2 ST-920, Clinical Trial Description

Table 3 ST-920, 7MM Market Size from 2020 to 2030 (in Million USD)

Table 4 Market Competitors

Table 5 Other Emerging Therapies

List of Figures

 Figure 1 The Development Timeline of ST-920

Figure 2 Patent Details, ST-920

Figure 3 ST-920, 7MM Market Size from 2020 to 2030 (in Million USD)

Figure 4 ST-920, US Market Size from 2020 to 2030 (in Millions USD)

Figure 5 ST-920, EU5 Market Size from 2020 to 2030 (in Millions USD)

Figure 6 ST-920, Japan Market Size from 2020 to 2030 (in Millions USD)

  • Tags:
  • ST-920
  • ST-920 Marketed Drugs Overview
  • ST-920 Market Assessment
  • ST-920 API Manufacturers/ Active P...
  • ST-920 US DMF
  • ST-920 US Drug Master Files
  • ST-920 Active Substance Master Fil...

Forward to Friend

Need A Quote